Publications

Department of Medicine faculty members published more than 3,000 peer-reviewed articles in 2022.

Phase I/II Trial of the MEK1/2 Inhibitor Trametinib (GSK1120212) in Relapsed/Refractory Myeloid Malignancies: Evidence of Activity in Patients with RAS Mutation-Positive Disease.

2012

Authors: Gautam Borthakur, Leslie Popplewell, Michael Boyiadzis, James M. Foran, Uwe Platzbecker, Norbert Vey, Walter B. Roland, Rebecca L. Olin, Azra Raza, Aristotles Giagounidis, Oliver G. Ottmann, Aref Al-Kali, Elias J. Jabbour, Tapan M. Kadia, Guillermo Garcia-Manero, John W. Bauman, Yuehui Wu, Yuan Liu, Dan Schramek, John Z. Zhu, Paul Wissel, Hagop M. Kantarjian

Blood

Single-Cell Pharmacodynamic Monitoring of Ribosomal Protein S6 Phosphorylation During AC220 Therapy Demonstrates in Vivo FLT3 Inhibition in Circulating Leukemic Blasts and Accurately Detects the Development of AC220 Resistance.

2012

Authors: Alexander E Perl, Grace R Jeschke, Catherine C Smith, James K. Mangan, Selina M. Luger, Martin Carroll

Blood

Single Molecule Real Time (SMRT™) Sequencing Sensitively Detects the Evolution of Polyclonal and Compound BCR-ABL Mutations in Patients Who Relapse On Kinase Inhibitor Therapy.

2012

Authors: Catherine C Smith, Michael Brown, Wendy T Parker, Kimberly Lin, Kevin Travers, Susana Wang, Susan Branford, Neil Shah

Blood

Crenolanib (CP-868,596) Is a Potent and Selective Type I FLT3 Inhibitor That Retains Activity Against AC220 Resistance-Causing FLT3 Kinase Domain Mutants.

2012

Authors: Catherine C Smith, Elisabeth Lasater, Melissa Mccreery, Kimberly Lin, Whitney Stewart, Lauren E Damon, Alexander E Perl, Grace R Jeschke, Mayumi Sugita, Martin Carroll, Scott C. Kogan, Neil Shah

Blood

Constitutively Activating Mutations At the FLT3 Activation Loop Residue D835 Are Associated with Clinical Resistance to AC220.

2012

Authors: Catherine C Smith, Jason Chin, Elisabeth Lasater, Amy L. Paguirigan, Kimberly Lin, Whitney Stewart, Sara Salerno, Lauren E Damon, Mark J. Levis, Alexander E Perl, Kevin Travers, Andrew Kasarskis, Jerald P. Radich, Neil Shah

Blood

Competitive Allele Specific TaqMan® PCR (castPCR™) Technology for Sensitive Detection of AC220-Resistant FLT3 Kinase Domain Mutations in Primary AML Patient Samples.

2012

Authors: Willard Cheng, Elisabeth Lasater, Catherine C Smith, Mouanoutoua Mokang, Yun Bao, Neil Shah

Blood

BCL6 Expression and Treatment Delay Correlate with Adverse Outcome in Newly Diagnosed Primary CNS Lymphoma: Final Report of CALGB 50202 (Alliance).

2012

Authors: James L. Rubenstein, Eric D. Hsi, Jeffrey L. Johnson, Sin-Ho Jung, Barbara Grant, Bruce D. Cheson, Lawrence D. Kaplan

The Journal of clinical endocrinology and metabolism

Total and high-molecular-weight adiponectin and risk of coronary heart disease and ischemic stroke in older adults.

2012

Authors: Kizer JR, Benkeser D, Arnold AM, Djousse L, Zieman SJ, Mukamal KJ, Tracy RP, Mantzoros CS, Siscovick DS, Gottdiener JS, Ix JH

Circulation

Associations of total and high-molecular-weight adiponectin with all-cause and cardiovascular mortality in older persons: the Cardiovascular Health Study.

2012

Authors: Kizer JR, Benkeser D, Arnold AM, Mukamal KJ, Ix JH, Zieman SJ, Siscovick DS, Tracy RP, Mantzoros CS, Defilippi CR, Newman AB, Djousse L

Diabetes care

Macro- and microstructural magnetic resonance imaging indices associated with diabetes among community-dwelling older adults.

2012

Authors: Falvey CM, Rosano C, Simonsick EM, Harris T, Strotmeyer ES, Satterfield S, Yaffe K